Trigen adds at both ends

Trigen Ltd.’s acquisition of ProCorde GmbH in a stock deal, which was to be announced this week, will allow it to integrate upstream while adding a set of preclinical compounds in the same cardiovascular space.

"We wanted to move upstream and were looking for a company targeting synergistic markets," said Sanjay Kakkar, CEO of Trigen

Read the full 548 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers